Date | Name | Title | Type | Security | Shares | Price | Value | Ownership | Reported |
06/08/2023 | McArthur James G | President and CEO | Sale | Common Stock | 2.4k | $16.04 | $38.2k | | 06/08/2023 |
06/08/2023 | McArthur James G | President and CEO | Exercise | Stock Option (Right to Buy) | 2.4k | $2.71 | $6.5k | | 06/08/2023 |
06/07/2023 | McArthur James G | President and CEO | Sale | Common Stock | 8.4k | $16.23 | $136.6k | | 06/06/2023 |
06/07/2023 | McArthur James G | President and CEO | Exercise | Stock Option (Right to Buy) | 8.4k | $2.71 | $22.8k | | 06/06/2023 |
06/06/2023 | McArthur James G | President and CEO | Sale | Common Stock | 18.2k | $16.18 | $293.7k | | 06/06/2023 |
06/06/2023 | McArthur James G | President and CEO | Exercise | Stock Option (Right to Buy) | 18.2k | $2.71 | $49.2k | | 06/06/2023 |
06/05/2023 | McArthur James G | President and CEO | Sale | Common Stock | 500 | $16.06 | $8k | | 06/02/2023 |
06/05/2023 | McArthur James G | President and CEO | Exercise | Stock Option (Right to Buy) | 500 | $2.71 | $1.4k | | 06/02/2023 |
06/02/2023 | McArthur James G | President and CEO | Exercise | Stock Option (Right to Buy) | 1.8k | $2.71 | $4.9k | | 06/02/2023 |
06/02/2023 | McArthur James G | President and CEO | Sale | Common Stock | 1.8k | $16.04 | $28.9k | | 06/02/2023 |
03/01/2023 | Donnelly Noel | CFO | Grant | Stock Option (Right to Buy) | 144k | $15.25 | $2.2M | | 03/01/2023 |
03/01/2023 | McArthur James G | President and CEO | Grant | Stock Option (Right to Buy) | 275k | $15.25 | $4.2M | | 03/01/2023 |
03/01/2023 | Svenstrup Niels | SVP, Chem. Mfg & Controls | Grant | Stock Option (Right to Buy) | 75k | $15.25 | $1.1M | | 03/01/2023 |
03/01/2023 | Goyal Jaya | EVP, Res. & Preclin. Dev. | Grant | Stock Option (Right to Buy) | 75k | $15.25 | $1.1M | | 03/01/2023 |
03/01/2023 | Mellion Michelle L | SVP, Clinical Development | Grant | Stock Option (Right to Buy) | 75k | $15.25 | $1.1M | | 03/01/2023 |
03/01/2023 | Mellion Michelle L | SVP, Clinical Development | Grant | Stock Option (Right to Buy) | 20k | $15.25 | $305k | | 03/01/2023 |
02/08/2023 | Goyal Jaya | EVP, Res. & Preclin. Dev. | Sale | Common Stock | 644 | $17.00 | $10.9k | | 02/06/2023 |
02/08/2023 | Goyal Jaya | EVP, Res. & Preclin. Dev. | Exercise | Stock Option (Right to Buy) | 644 | $10.88 | $7k | | 02/06/2023 |
02/07/2023 | Goyal Jaya | EVP, Res. & Preclin. Dev. | Sale | Common Stock | 3.7k | $17.18 | $63.2k | | 02/06/2023 |
02/07/2023 | Goyal Jaya | EVP, Res. & Preclin. Dev. | Exercise | Stock Option (Right to Buy) | 3.7k | $10.88 | $40k | | 02/06/2023 |
02/06/2023 | Goyal Jaya | EVP, Res. & Preclin. Dev. | Exercise | Stock Option (Right to Buy) | 1.7k | $10.88 | $18.2k | | 02/06/2023 |
02/06/2023 | Goyal Jaya | EVP, Res. & Preclin. Dev. | Sale | Common Stock | 1.7k | $17.04 | $28.6k | | 02/06/2023 |
12/19/2022 | Svenstrup Niels | SVP, Chem. Mfg & Controls | Exercise | Stock Option (Right to Buy) | 10k | $2.71 | $27.1k | | 12/19/2022 |
10/03/2022 | Dable Habib J | Director | Grant | Stock Option (Right to Buy) | 22.7k | $9.31 | $211.2k | | 10/03/2022 |
07/01/2022 | Mellion Michelle L | SVP, Clinical Development | Grant | Stock Option (Right to Buy) | 100k | $10.21 | $1M | | 07/01/2022 |
05/10/2022 | Oxford Science Enterprises plc | 10% Owner | Conversion | Series A-1 Preferred stock | 1.3M | $0.00 | $0 | | 05/10/2022 |
05/10/2022 | Oxford Science Enterprises plc | 10% Owner | Conversion | Series A-2 Preferred stock | 962.9k | $0.00 | $0 | | 05/10/2022 |
05/10/2022 | Oxford Science Enterprises plc | 10% Owner | Conversion | Common Stock | 1.5M | $0.00 | $0 | | 05/10/2022 |
05/10/2022 | Oxford Science Enterprises plc | 10% Owner | Conversion | Series B Preferred stock | 1.6M | $0.00 | $0 | | 05/10/2022 |
05/10/2022 | Flynn James E | 10% Owner | Conversion | Common Stock | 268.5k | $0.00 | $0 | Through Deerfield Partners, L.P. | 05/10/2022 |
05/10/2022 | Flynn James E | 10% Owner | Purchase | Common Stock | 208.3k | $12.00 | $2.5M | Through Deerfield Partners, L.P. | 05/10/2022 |
05/10/2022 | Flynn James E | 10% Owner | Conversion | Series B Preferred Stock | 273.3k | $0.00 | $0 | Through Deerfield Partners, L.P. | 05/10/2022 |
05/10/2022 | Oxford Science Enterprises plc | 10% Owner | Conversion | Common Stock | 1.3M | $0.00 | $0 | | 05/10/2022 |
05/10/2022 | Oxford Science Enterprises plc | 10% Owner | Conversion | Common Stock | 945.9k | $0.00 | $0 | | 05/10/2022 |
05/10/2022 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Conversion | Common Stock | 3.6M | $0.00 | $0 | See footnotes | 05/10/2022 |
|